Search results
We review clinical development of remdesivir, a prodrug with a demonstrated ability to inhibit SARS-CoV-2 replication, which supports its clinical evaluation for COVID-19 treatment.
Subsequent evaluation by numerous virology laboratories demonstrated the ability of remdesivir to inhibit coronavirus replication, including SARS-CoV-2. Here, we provide an overview of remdesivir’s discovery, mechanism of action, and the current studies exploring its clinical effectiveness.
28 wrz 2021 · Great efforts have been put into the development of novel drugs against SARS-CoV-2 infection. Currently, remdesivir (RDV) (Fig. 1a), an intravenously administered nucleotide prodrug, is...
27 sie 2021 · Remdesivir (RDV), formerly known as GS-5734, is a 1-cyano-substituted adenine C-nucleoside ribose analog that inhibits the RdRp of many viruses. In human macrophages, RDV exposure causes an accumulation of the drug, which is then rapidly converted into its active triphosphate metabolite.
Remdesivir (formerly GS‐5734) is a nucleoside analogue pro‐drug currently being evaluated in COVID‐19 clinical trials. Its unique structural features allow high concentrations of the active triphosphate metabolite to be delivered intracellularly and it evades proofreading to successfully inhibit viral RNA synthesis.
RDV is the most widely investigated antiviral drug for the treatment of COVID-19. This attention on RDV activity against SARS-CoV-2 is justified by promising in vitro studies, which demonstrated that RDV was able to suppress viral replication without significant toxicity.
17 sie 2023 · Unlike some antivirals, remdesivir has a low potential for drug-drug interactions. In the pivotal ACTT-1 trial in hospitalized patients with COVID-19, daily intravenous infusions of remdesivir significantly reduced time to recovery relative to placebo.
